OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the tre
OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Okyo Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on Nasdaq at $1.54 per share.
OKYO - Another insider buy: Okyo Pharma Limited, a clinical-stage biopharmaceutical company developing investigational Therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Okyo Pharma’s Chief Executive Officer, Robert J.
Dempsey, has purchased 15,000 of the Company’s ordinary shares on Nasdaq at $1.54 per share.